Hospital
HMH Hospitals Corporation
HMH Hospitals Corporation was paid $65.37M by Medicaid between Jan 2018 and Dec 2024, across 339 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoHMH HOSPITALS CORPORATION
PERTH AMBOY, NJ 08861
PERTH AMBOY, NJ 08861
33aNPI1790297455assigned 11/02/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$65.37M
24GClaims1,191,418
24DCodes billed339
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#26 of 93
Median peer was paid$30.60M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 83,228 | $5.25M | |
| 2019 | 171,066 | $10.71M | |
| 2020 | 123,130 | $7.61M | |
| 2021 | 163,874 | $9.85M | |
| 2022 | 219,993 | $11.47M | |
| 2023 | 243,145 | $11.78M | |
| 2024incomplete | 186,982 | $8.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 45,062 | 41,252 | $14.88M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 40,687 | 36,897 | $14.20M |
| G0378 | Hospital observation service, per hour | 8.7% | 8,634 | 7,036 | $5.70M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 15,042 | 14,136 | $2.89M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 10,295 | 9,460 | $2.37M |
| S9480 | Intensive outpatient psychiatric services, per diem | 3.5% | 3,496 | 2,921 | $2.27M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.4% | 1,853 | 1,773 | $2.21M |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.6% | 8,879 | 6,409 | $1.01M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 23,333 | 5,897 | $961K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.4% | 7,660 | 7,514 | $884K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.1% | 8,782 | 7,603 | $729K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.1% | 574 | 563 | $727K |
327 more codes
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 1.0% | 19,270 | $679K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,961 | $635K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,103 | $612K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 19,565 | $598K |
| 76830 | Ultrasound, transvaginal | <1% | 5,097 | $540K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 395 | $452K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,880 | $449K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27,953 | $438K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,778 | $409K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,657 | $373K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,184 | $358K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,665 | $347K |
| 80053 | Comprehensive metabolic panel | <1% | 52,757 | $333K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,706 | $331K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,322 | $304K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,881 | $285K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,401 | $266K |
| 95886 | <1% | 1,072 | $264K | |
| 76813 | <1% | 2,060 | $247K | |
| 95911 | <1% | 716 | $246K | |
| 93017 | <1% | 1,292 | $244K | |
| OP370 | <1% | 7,133 | $239K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 11,166 | $233K |
| 76642 | <1% | 2,411 | $229K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,126 | $218K |
| OP272 | <1% | 8,878 | $216K | |
| 97010 | <1% | 20,865 | $216K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 4,772 | $212K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,321 | $204K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,407 | $203K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 8,129 | $199K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,637 | $192K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,526 | $185K |
| 77066 | Tomosynthesis, mammo | <1% | 1,193 | $176K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,550 | $175K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 904 | $170K |
| 77080 | <1% | 1,707 | $158K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 55,442 | $158K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 198 | $149K |
| 93970 | <1% | 600 | $145K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,779 | $136K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,598 | $127K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,888 | $125K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,049 | $124K |
| OP710 | <1% | 2,764 | $123K | |
| 76801 | <1% | 1,259 | $122K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,033 | $117K |
| 93971 | <1% | 897 | $113K | |
| 72110 | <1% | 2,929 | $110K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,240 | $94K |
| 36415 | Collection of venous blood by venipuncture | <1% | 57,714 | $89K |
| 97035 | <1% | 5,329 | $85K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 5,188 | $85K |
| OP250 | <1% | 97,248 | $84K | |
| 97161 | <1% | 1,455 | $83K | |
| 73564 | <1% | 2,945 | $83K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,924 | $81K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,877 | $81K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,111 | $79K |
| 97162 | <1% | 1,991 | $79K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,642 | $78K |
| 76770 | <1% | 903 | $76K | |
| 73630 | <1% | 3,482 | $75K | |
| 76536 | <1% | 666 | $66K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,917 | $59K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 126 | $57K |
| 59025 | Fetal non-stress test | <1% | 711 | $56K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,434 | $55K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,044 | $50K |
| 0002A | <1% | 1,240 | $49K | |
| 73030 | <1% | 2,477 | $48K | |
| 80061 | Lipid panel | <1% | 3,700 | $46K |
| 0001A | <1% | 1,264 | $46K | |
| 72052 | <1% | 1,169 | $46K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 906 | $46K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,073 | $42K |
| 85027 | <1% | 6,834 | $41K | |
| 84484 | <1% | 19,578 | $41K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,952 | $40K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,989 | $39K |
| 73610 | <1% | 2,604 | $37K | |
| OP258 | <1% | 44,812 | $31K | |
| 83735 | <1% | 6,664 | $31K | |
| 81025 | <1% | 21,737 | $30K | |
| 73130 | <1% | 2,011 | $30K | |
| 0012A | <1% | 897 | $29K | |
| 74018 | <1% | 1,721 | $28K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 729 | $27K |
| 0011A | <1% | 934 | $27K | |
| OP270 | <1% | 5,478 | $26K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,398 | $26K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,952 | $26K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,052 | $25K |
| 81001 | <1% | 21,123 | $24K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,758 | $24K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,753 | $23K |
| 73110 | <1% | 1,358 | $21K | |
| 82962 | <1% | 13,658 | $21K | |
| 83880 | <1% | 4,462 | $20K | |
| 93458 | <1% | 12 | $19K | |
| 93976 | <1% | 94 | $19K | |
| 0004A | <1% | 444 | $18K | |
| 84439 | <1% | 2,063 | $18K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 342 | $18K |
| 0064A | <1% | 519 | $18K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 751 | $18K |
| 83690 | <1% | 16,132 | $17K | |
| 85610 | <1% | 5,847 | $17K | |
| 97116 | <1% | 1,497 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,965 | $16K |
| 82607 | <1% | 1,434 | $16K | |
| 85730 | <1% | 4,482 | $16K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 431 | $15K |
| 76820 | <1% | 247 | $15K | |
| 86850 | <1% | 4,629 | $15K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 148 | $14K |
| 81003 | <1% | 14,015 | $14K | |
| 87040 | <1% | 2,064 | $14K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,989 | $14K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,999 | $13K |
| J2704 | Injection, propofol, 10 mg | <1% | 6,257 | $13K |
| 82077 | <1% | 6,465 | $13K | |
| 84702 | <1% | 4,308 | $12K | |
| 90715 | <1% | 1,503 | $12K | |
| 0071A | <1% | 239 | $12K | |
| 96376 | <1% | 1,102 | $11K | |
| 73502 | <1% | 691 | $11K | |
| 87070 | <1% | 7,319 | $11K | |
| 0072A | <1% | 212 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,522 | $10K |
| 88342 | <1% | 806 | $10K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,075 | $9K |
| 88313 | <1% | 906 | $9K | |
| 71250 | <1% | 72 | $9K | |
| 86900 | <1% | 4,722 | $9K | |
| A0434 | Specialty care transport (sct) | <1% | 17 | $9K |
| 84704 | <1% | 446 | $9K | |
| 76821 | <1% | 128 | $9K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 68 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,715 | $8K |
| 86901 | <1% | 4,722 | $8K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 157 | $8K |
| 70486 | <1% | 182 | $8K | |
| A0425 | Ground mileage, per statute mile | <1% | 157 | $7K |
| J3490 | Unclassified drugs | <1% | 1,811 | $7K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,177 | $7K |
| 96367 | <1% | 208 | $7K | |
| 97014 | <1% | 119 | $7K | |
| 83615 | <1% | 401 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 484 | $7K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 124 | $7K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,613 | $6K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 15 | $6K |
| 84100 | <1% | 3,250 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 945 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 948 | $6K |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 592 | $6K |
| 72072 | <1% | 176 | $6K | |
| 88312 | <1% | 1,077 | $5K | |
| 73080 | <1% | 401 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $5K |
| 83605 | <1% | 1,531 | $5K | |
| 85651 | <1% | 1,583 | $5K | |
| 12001 | <1% | 352 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,274 | $5K |
| 82105 | <1% | 270 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,389 | $4K |
| S9484 | Crisis intervention mental health services, per hour | <1% | 237 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,707 | $4K |
| 82550 | <1% | 2,563 | $4K | |
| 87400 | <1% | 3,379 | $4K | |
| 80143 | <1% | 1,885 | $4K | |
| 85379 | <1% | 2,324 | $4K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 677 | $4K |
| 80179 | <1% | 1,880 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,469 | $3K |
| 84163 | <1% | 186 | $3K | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 446 | $3K |
| 0054A | <1% | 80 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,025 | $3K |
| 73590 | <1% | 253 | $3K | |
| 82570 | <1% | 1,260 | $3K | |
| 82948 | <1% | 611 | $3K | |
| 87186 | <1% | 1,427 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,324 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,729 | $3K |
| 93226 | <1% | 32 | $3K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,366 | $3K |
| 74240 | <1% | 26 | $3K | |
| 93925 | <1% | 13 | $3K | |
| 82248 | <1% | 282 | $3K | |
| 97802 | <1% | 13 | $2K | |
| 97032 | <1% | 221 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 616 | $2K |
| 0031A | <1% | 74 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,034 | $2K |
| 72081 | <1% | 43 | $2K | |
| 80306 | <1% | 1,097 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 31 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 18 | $2K |
| 93225 | <1% | 32 | $2K | |
| 70360 | <1% | 62 | $2K | |
| 88304 | <1% | 176 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,949 | $2K |
| 73140 | <1% | 166 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,435 | $2K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 305 | $2K |
| 74022 | <1% | 184 | $2K | |
| 97163 | <1% | 27 | $1K | |
| 82043 | <1% | 318 | $1K | |
| 87420 | <1% | 793 | $1K | |
| 84481 | <1% | 68 | $1K | |
| 71101 | <1% | 98 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 927 | $1K |
| 72082 | <1% | 13 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,618 | $1K |
| 74019 | <1% | 175 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,103 | $1K |
| J3590 | Unclassified biologics | <1% | 12 | $1K |
| 82728 | <1% | 77 | $993.44 | |
| 0052A | <1% | 20 | $980.89 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,173 | $897.00 |
| 70496 | <1% | 12 | $872.95 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 163 | $855.40 |
| 76870 | <1% | 28 | $843.90 | |
| 0134A | <1% | 48 | $834.68 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 15 | $832.72 |
| 86140 | <1% | 276 | $829.45 | |
| 73090 | <1% | 76 | $792.94 | |
| 0051A | <1% | 15 | $775.81 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 645 | $726.29 |
| 82746 | <1% | 89 | $709.33 | |
| 90785 | <1% | 337 | $693.24 | |
| 0034A | <1% | 16 | $656.70 | |
| 80076 | <1% | 197 | $649.00 | |
| 97165 | <1% | 13 | $632.60 | |
| 82247 | <1% | 103 | $620.58 | |
| 87088 | <1% | 650 | $610.65 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 217 | $608.00 |
| 83655 | <1% | 26 | $590.78 | |
| 85007 | <1% | 318 | $587.14 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 164 | $573.16 |
| 73562 | <1% | 56 | $572.20 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 14 | $561.42 |
| 15853 | <1% | 38 | $550.88 | |
| 82010 | <1% | 435 | $534.42 | |
| 12002 | <1% | 13 | $515.96 | |
| 84153 | <1% | 28 | $501.81 | |
| 83550 | <1% | 81 | $495.22 | |
| 73523 | <1% | 12 | $486.47 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 118 | $458.60 |
| OP259 | <1% | 28 | $448.87 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 312 | $392.40 |
| G0008 | Administration of influenza virus vaccine | <1% | 97 | $387.98 |
| 93880 | <1% | 15 | $382.89 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 12 | $378.30 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 214 | $375.98 |
| 84145 | <1% | 112 | $374.16 | |
| 83540 | <1% | 81 | $355.74 | |
| 91300 | <1% | 2,403 | $353.00 | |
| 72131 | <1% | 35 | $325.52 | |
| 0124A | <1% | 20 | $321.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 62 | $318.58 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 69 | $318.58 |
| 86769 | <1% | 15 | $306.89 | |
| 86593 | <1% | 84 | $258.16 | |
| 84550 | <1% | 90 | $257.49 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $248.06 |
| A4618 | Breathing circuits | <1% | 1,871 | $247.58 |
| 90686 | <1% | 26 | $245.29 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $245.25 |
| 91301 | <1% | 1,537 | $237.00 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12 | $222.00 |
| 73552 | <1% | 12 | $216.13 | |
| 87077 | <1% | 176 | $215.75 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 219 | $214.40 |
| 12011 | <1% | 31 | $202.56 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 333 | $187.22 |
| 86039 | <1% | 12 | $181.62 | |
| 82800 | <1% | 69 | $163.31 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 196 | $153.16 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 81 | $144.98 |
| 80329 | <1% | 185 | $130.19 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 941 | $120.67 |
| C1769 | Guide wire | <1% | 36 | $120.48 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 18 | $112.78 |
| 87486 | <1% | 15 | $109.99 | |
| 87581 | <1% | 17 | $109.99 | |
| 83930 | <1% | 66 | $103.47 | |
| 86803 | <1% | 16 | $91.20 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 103 | $89.76 |
| 87147 | <1% | 174 | $85.82 | |
| 82150 | <1% | 29 | $82.27 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 66 | $80.00 |
| 84703 | <1% | 82 | $75.71 | |
| 91307 | <1% | 421 | $75.01 | |
| 82803 | <1% | 40 | $73.03 | |
| OP637 | <1% | 3,910 | $69.04 | |
| 29130 | <1% | 14 | $57.19 | |
| 91306 | <1% | 475 | $57.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 26 | $55.00 |
| 73060 | <1% | 19 | $54.34 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 158 | $52.22 |
| 84132 | <1% | 123 | $50.47 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 67 | $50.11 |
| 84436 | <1% | 20 | $47.00 | |
| 84156 | <1% | 114 | $46.31 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 83 | $42.02 |
| 86141 | <1% | 14 | $32.52 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 37 | $32.49 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 19 | $28.88 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 36 | $26.77 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 30 | $24.15 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 36 | $19.36 |
| 91305 | <1% | 144 | $19.00 | |
| 94760 | <1% | 14 | $16.63 | |
| 82040 | <1% | 18 | $14.83 | |
| 91303 | <1% | 53 | $12.00 | |
| 84155 | <1% | 19 | $10.83 | |
| 85045 | <1% | 13 | $9.98 | |
| 80320 | <1% | 14 | $6.12 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 86 | $5.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 13 | $1.16 |
| 91313 | <1% | 47 | $1.00 | |
| 88300 | 0% | 12 | $0.00 | |
| 91312 | 0% | 18 | $0.00 | |
| 84450 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSAWCZUK, IHOR (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| HMH Hospitals Corporation | Hackensack, NJ | $333.03M |
| HMH Hospitals Corporation | North Bergen, NJ | $79.26M |
| HMH Hospitals Corporation | Brick, NJ | $49.91M |
| HMH Hospitals Corporation | Holmdel, NJ | $29.33M |
| HMH Hospitals Corporation | Red Bank, NJ | $26.39M |
| HMH Hospitals Corporation | Old Bridge, NJ | $18.66M |
| HMH Hospitals Corporation | Brick, NJ | $575K |
| Hackensack Specialty Care Associates, PC | Hackensack, NJ | $141K |
| Humc Medical Observation | Hackensack, NJ | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.